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Abstract description: Opioid abuse, addiction, and overdose is a serious public health concern 
that has plagued the healthcare system for the last thirty years. The compiled research in the 
following paper explores the rise of the opioid epidemic, the implications of more recent 
prescription monitoring and pain management programs, the relationship between non-
prescription and prescription opioids, and the current face of the epidemic, illicit opioids. 
Kentucky has, unfortunately, been at the forefront of this epidemic with regard to both 
prescription and illicit opioids.  Policy reformation and preventative action must be taken into 
consideration in regard to the relationship between prescription and non-prescription opioid use. 
Addressing the relationship is crucial to ensure by fighting one addiction we are not 
unknowingly promoting another in order to effectively turn the tide on the opioid epidemic.  
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The opioid epidemic has evolved rapidly throughout the last decade. The abuse of 
and addiction to opioids is a prevalent national crisis, with more than 130 people dying 
from opioid-related drug overdoses a day (Health Resources and Administration 2020). 
In the late 1990’s healthcare providers began to prescribe these pain relievers at greater 
rates, which ultimately led to the widespread diversion and misuse of the medications 
seen today. In 2018, 67,367 drug overdose deaths occurred in the United States, with 
opioids being involved in 46,802 of the overdose deaths (69.5% of all drug overdose 
deaths). Two out of three (67.0%) opioid-involved overdose deaths involve synthetic 
opioids (CDC 2019). An estimated 1.7 million people in the United States suffered from 
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substance use disorders related to prescription opioid pain relievers, and 652,000 suffered 
from a heroin use disorder. An estimated 4 to 6 % who misuse prescription opioids 
transition to heroin, and about 80% of people who use heroin first misused prescription 
opioids (National Institute on Drug Abuse 2020). In addition to increases in opioid 
misuse, addiction, and overdose, the opioid epidemic contributes to an increase of 
neonatal abstinence syndrome due to opioid misuse during pregnancy and the spread of 
HIV and hepatitis C by intravenous injection.  
 While these data are alarming, among 38 states with prescription opioid overdose 
death data, 17 states saw a decline between 2017-2018, and none experienced a 
significant increase. Addressing overprescribing of opioids through prescription 
monitoring and improved pain management has been pivotal in combatting the crisis; 
however, there is still much work to be done. An analysis of the opioid epidemic reveals 
a challenge facing the healthcare system: illicit opioids, such as heroin and fentanyl, have 
increased in frequency of abuse and overdose despite the decrease in prescription opioids. 
The healthcare system should shift focus to combat the new face of the epidemic. 
 
OPIOID PHARMACOLOGY  
 To better understand the epidemic and create a curative path to combat it, basic 
opioid pharmacology should be noted. Opioids are a class of drugs that work to produce a 
variety effects, but primarily pain relief. Opioid pharmacology was born when morphine 
was first isolated from opium in 1806 by Sertürner. By 1847 the chemical formula for 
morphine (C₁₇H₁₉NO₃) was deduced, which coupled with the invention of the hypodermic 
needle in 1853 led to more precise and widespread clinical use of morphine for the first 
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time (Blackmore and White 2002). Morphine is considered the archetypal opioid and 
consists of a benzene ring with a phenolic hydroxyl group at position 3 and an alcohol 
hydroxyl group at position 6 and at the nitrogen atom. In addition to morphine, three 
other naturally occurring alkaloids can also be extracted from P. somniferum (Opium 
Poppy): codeine, papaverune, and thebaine. Chemical manipulations of the opiate 
alkaloids in the 19th Century began to yield many semi-synthetic opioids, such as 
diamorphine, dihydrocodeine, buprenorphine, nalbuphine, naloxone and oxycodone, that 
became useful in the practice of medicine. Following suit, the 20th Century saw the 
production of a multitude of synthetic opioids. Synthetic opioids can be divided into four 
chemical groups: the morphinan derivatives (levorphanol, butorphanol), the 
diphenylheptane derivatives (methadone, propoxyphene), the benzomorphan derivatives 
(pentazocine, phenazocine) and the phenylpiperidine derivatives (pethidine, alfentanil, 
fentanyl, sufentanil and remifentanil) (Pathan and Williams 2012).  
 Additionally, opioids can also be grouped in regard to their effect at opioid 
receptors. Opioid agonists produce the maximal response by stimulating the receptor. 
Partial agonists bind to the receptors, but only give a partial functional response 
(Buprenorphine). Antagonists bind to receptors, produce no functional response, and 
prevent agonists from binding to that receptor (Naloxone). There are three opioid 
receptors, DOP (the delta receptor), KOP (the kappa receptor) and MOP (the mu 
receptor). Each receptor is a G-protein-coupled receptor, controlled by different genes, 
and are widely distributed primarily within the central nervous system (CNS) and 
throughout the peripheral tissues. There is a series of endogenous ligands active at the 
receptors that are derived from parent compounds provided from three pro-hormone 
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precursors (Trescott et al., 2008). Table 1 is below detailing opioid receptors and their 
respective endogenous ligands and precursors.  
 
Receptor Precursor Endogenous Ligands 
DOP Pro-enkephalin Met-enkephalin,  
Leu-enkephalin 
KOP Pro-dynorphin Dynorphin-A, Dynorphin-
B 
MOP Pro-opiomelancortin β-endorphin 
Table 1. Opioid Receptors Broken Down.  
 
 The stimulation of each opioid receptor produces a range of effects, which are 
dependent on the location of the receptor. Agonists binding to MOP receptors may cause 
analgesia, sedation, respiratory depression, bradycardia, nausea and vomiting, and a 
reduction in gastric motility. Additionally, agonists binding to DOP receptors can cause 
spinal and supraspinal analgesia and reduce gastric motility, while KOP receptor 
activation can produce spinal analgesia, diuresis, and dysphoria (Trescott et al., 2008).  
 The chemical structure of opioids can be further subdivided:  
• 4,5-epoxymorphinan ring = morphine, codeine, oxymorphone, oxycodone, 
buprenorphine, hydromorphone and hydrocodone 
• Phenylpiperidines = alfentanil and fentanyl,  
• Diphenylheptylamines = methadone.  
Although these compounds differ in chemical structure, physicochemical properties and 
in pharmacokinetics, they have one common feature, which is their interaction with the 
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MOP receptor as the primary target. All opioids used in clinical practice today exert their 
action at the MOP receptor, with some having additional activity at one of the previously 
mentioned receptors (Drewes et al.,2012).  
 
THE THREE WAVES 
 The rise of the opioid epidemic can be divided into three waves. The first wave 
began in the early 1990s following a significant increase in the prescribing of opioid 
medications for pain treatment. Prior to this decade painkillers derived from the opium 
poppy were typically only written as prescriptions for patients with advanced cancer or 
other terminal conditions. Dr. Russell Portenoy, MD, pain specialist and neurologist, was 
acclaimed as the “King of Pain” after he became a trailblazer for wider prescription of 
opioids for pain treatment and management. Portenoy and company hemmed a movement 
to enhance this group of painkillers. The movement was branded with the proclamation 
that not treating pain properly amounted to medical negligence and that the risks of 
opioids were minimal compared to what was believed (Gale 2016). Lectures and writing 
on the subject often referenced a study published in The New England Journal of 
Medicine by Dr. Hershel Jick, MD, and graduate student, Jane Porter, in 1980. The study 
concluded “that despite widespread use of narcotic drugs in hospitals, the development of 
addiction is rare in medical patients with no history of addiction” with data suggesting 
four out of 11,882 hospitalized patients who received at least one narcotic and had no 
prior history of addiction, documented addiction (Jick and Porter 1980). The study was 
invoked by doctors and pharmaceutical companies to promote to the medical community 
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that opioids are not very addictive.  This reassurance contributed to many healthcare 
providers writing opioid prescriptions at much greater rates for non-cancer related pain. 
 Porter and Jick’s acclaimed study that sparked the movement was widely 
misinterpreted as it did not account for patients after their hospital stay (Gale 2016). By 
1999, 86% of patients on opioids were using them for non-cancer pain (Leu et al., 2020). 
The Joint Commission on Accreditation of Healthcare Organizations endorsed this 
treatment and established new standards in 2001 that held hospitals and physicians 
responsible for ensuring adequate pain treatment (Chidgey et al., 2019). From 1999 to 
2014 opioid prescriptions quadrupled and there were more than 165,000 deaths related to 
opioid overdose (CDC 2016). The second wave of the opioid epidemic began in the 
following decade marked with a significant increase in opioid deaths involving heroin, 
increasing by 286% from 2002 to 2013 (Leu et al., 2020). Due to the implementation of a 
multitude of drug monitoring programs it became increasingly more difficult to obtain a 
prescription opioid, which shifted the focus to the cheaper and more accessible 
alternative with similar effects, heroin. Approximately 80% of heroin users first misused 
prescription opioids before turning to heroin (National Institute on Drug Abuse 2020).  
 The third wave began shortly after in 2013, this time with a significant increase in 
overdose deaths involving illicitly manufactured fentanyl. Fentanyl is a synthetic opioid, 
50 to 100 times more potent than morphine. The drug is sold as a “powder, dropped onto 
blotter paper, put in eye droppers and nasal sprays, or made into pills that look like other 
prescription opioids” (National Institute on Drug Abuse 2020). Illicit fentanyl abuse has 
continued to consistently increase over the course of the decade. Overdose deaths 
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involving synthetic opioids, fentanyl and fentanyl analogs, were 12 times higher in 2019 
than in 2013 (CDC 2020).  
 A common theme in opioid literature is attempting to place blame on someone or 
something for the origin of the opioid epidemic; however, it cannot be pinpointed to one 
certain movement or only one pharmaceutical company. The healthcare system failed, 
but with good intentions. The Food and Drug Administration (FDA) approved 
Oxycontin®, manufactured by Purdue Pharmaceuticals, in 1995. The active ingredient of 
oxycontin is oxycodone, a semisynthetic narcotic analgesic, used for pain management 
(Jayawant and Balkrishnan 2005). Purdue Pharmaceuticals led an aggressive marketing 
campaign that promoted Oxycontin® as “smooth and sustained pain control all day and 
all night” (Purdue Pharma popular timelines). Additionally, the campaign promoted 
Oxycontin’s® extended-release formulation by claiming that one dose could relieve pain 
for 12 hours, more than twice the duration of other pain medications on the market at the 
time. This caught the attention of physicians and patients alike as it would prevent 
interruption of sleep and daily activities, with promising lower abuse potential since the 
drug would be absorbed slowly. Oxycontin® produced $31 billion in revenue for Purdue 
Pharmaceuticals (LA Times**). However, this vision was too good to be true. Purdue 
Pharmaceuticals’ clinical trials conducted for FDA approval reported that many patients 
given Oxycontin® were asking for more pain medication before their next dose 
scheduled 12 hours later (Chow 2020). Despite these results Purdue Pharmaceuticals still 
went to the FDA for approval and went on to produce advertisements in medical journals 
claiming pain relief in patients can be achieved by the 12-hour dosage regimen. The FDA 
based its judgment on marketing history of MS Contin, “a similar controlled-release 
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formulation of morphine used in the medical community since 1987, without significant 
reports of abuse and misuse (FDA).” 
 After FDA approval, the number of prescriptions of Oxycontin® increased to 
over 14 million in 2001, up from 316,000 prescriptions in 1996. This increase in 
prescriptions saw sales increase to nearly $3 billion, in comparison to the $44 million in 
1996 (Van Zee 2009). The commercial success of Oxycontin® was astounding; however, 
it was followed by increasing rates of abuse, addiction, and overdose. Abusers began to 
crush the tablets and snort the powder or dissolve them in water and inject the drug for a 
fast, intense morphine-like high (Jayawant and Balkrishnan 2005). In 2002, federal 
prosecutors with the Justice Department began an investigation on Purdue 
Pharmaceuticals after receiving reports pills were being crushed, snorted, and injected, 
stolen from pharmacies, and sold illegally (NY Times). It was not until 2003 that the 
media added a spotlight on the investigation. This occurred because Rush Limbaugh, 
radio host, admitted to listeners on his national radio show that was addicted to 
painkillers and “would immediately enter a 30-day treatment program” (Bennett and 
Pacenti 2003). Limbaugh’s personal statement came a week after news outlets reported 
Limbaugh was being investigated for illegally obtain prescription drugs. Limbaugh 
admitted the origins of his addictions stemmed from when his doctor prescribed 
painkillers to treat post-surgical pain following a botched spinal surgery. Limbaugh chose 
to treat the severe pain with prescribed painkillers instead of an additional surgery 
(Bennett and Pacenti 2003). Limbaugh’s personal statement sent the media into a frenzy 
with headlines focusing on the abuse of Oxycontin®. The growing attention from the 
media gave even more reason for federal prosecutors to thoroughly continue their 
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investigation on Purdue Pharmaceuticals.  
 After the four-year investigation, the officials determined that Purdue 
Pharmaceuticals was aware of the abuse and addiction reports yet continued to market the 
drug aggressively. The prosecutors recommended the top three Purdue Pharmaceuticals 
executives be indicted on felony charges; however, the Justice Department did not follow 
the recommendation (NY Times). Purdue Pharmaceuticals executives did however plead 
guilty to misdemeanor charges with a community service agreement in 2007 (NPR 2019).  
 
PRESCRIPTION DRUG MONITORING PROGRAMS 
The mere guilty plea did not fix the damage that was already done in regard to 
opioid abuse and addiction. The DEA recognized this and began developing drug abuse 
monitoring programs to address the opioid crisis. A prescription drug monitoring 
program (PDMP) is an electronic database that tracks controlled substance prescriptions 
at the state level to help mitigate prescription misuse and diversion. These programs were 
individualized for each state and designed to uphold state laws ensuring access to 
appropriate pharmaceutical care and deterring diversion. PDMPs facilitate 
communication among the healthcare system, specifically between pharmacists and 
healthcare providers, as well as state insurance programs, healthcare licensure boards, 
health departments, and law enforcement.  
PDMPs were established with features that allow healthcare providers to access 
patients’ prescribing histories to inform their prescribing decisions. Additionally, before 
pharmacists dispense controlled substances, they log the prescription information into the 
state PDMP—the rate the information is submitted varies from state to state and 
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pharmacy to pharmacy, ranging from monthly to daily to in real time (CDC 2020). Real-
time use maximizes the benefit of PDMPs, as well as constantly managing and evaluating 
the program as the face of the epidemic changes. Currently, 49 states, the District of 
Columbia, and the US territory Guam have implemented PDMP legislation. Missouri is 
the only state without a PDMP, however, Faisal Khan, former head of the St. Louis 
County Health Department, led a voluntary county based PDMP program in 2017 that 
now covers other areas of the state (Weber 2019). Based on the experience of PDMPs in 
the past, those PDMPs implemented more recently have been implemented faster with 
more innovative resources.  
The first PDMP was implemented by New York state in 1918. Drugs, such as 
heroin and cocaine were allowed to be prescribed by federal and state laws. The 
legislation was enacted to monitor prescriptions for cocaine, heroin, codeine, morphine, 
and opium. Pharmacists were required to report prescriptions for cocaine, heroin, 
codeine, morphine, and opium to the health department within 24 hours of dispensing the 
drug. The program was only in effect for three years before it was ultimately eliminated; 
however, it would go to serve as the blueprint for many PDMPs to come (TAG 2018).  
California established their own statewide PDMP in 1939 that has been in 
continuous operation since. California originally placed their administration in a newly 
created Bureau of Narcotic Enforcement. Hawaii followed their lead in 1943 and many 
other states followed suit during the 1960’s and 70’s. In the beginning all PDMPs had the 
same characteristics that included collecting prescription information on Schedule II 
controlled substances, requiring multi-copy state issued prescription forms to prescribe 
and dispense Schedule II substances, and requiring sending prescription information to 
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the state within 30 days from the time the drug was dispensed. The new wave of 
monitoring prescriptions was put in question in front of the Supreme Court with Roe v. 
Whalen 1977 when challenges were raised regarding legality of New York state’s 
Controlled Substance Act. The supreme court ruled that “New York state does have the 
authority to collect the information as part of its police powers … was not 
unconstitutional and did not violate patient confidentiality” (TAG 2018). The ruling 
granted continuation of New York’s PDMP, while indirectly opening the door for other 
states to pass PDMP laws at the start of the 21st Century when opioid abuse, addiction, 
and overdose reached a new high.  
 Twenty-seven states implemented PDMPs from 2000 to 2010 (SAMHSA 2017). 
Oversight of all controlled substances is now recommended including Schedule II 
through V drugs, as well as controlled non-opioids such as stimulants (D’Souza et al., 
2020). Each PDMP is still individual to each state typically following one of the three 
models. One of these models is operated through non-mandated use, which allows 
prescribers and pharmacists to access the database voluntarily. A second model involves 
proactive reporting, which allows prescribers and pharmacists to receive unsolicited 
reports on patients who are on a combination of controlled medications or a potentially 
dangerous dose and on patients who receive prescriptions from multiple providers. The 
third, newer model features mandated use and requires prescribers to review their 
respective PDMP before prescribing any controlled substance. The mandated use model 
has now been adopted in Kentucky, Tennessee, New York, and Ohio (D’Souza et al., 





 Kentucky has, unfortunately, been at the forefront of the opioid epidemic for 
many years. Between 2000 and 2013, the number of drug overdose deaths in Kentucky 
rose from 246 (6.1 per 100,000 population) to 1,019 (23.2 per 100,000 population) 
(American Public Health Association). To address the epidemic Kentucky first 
implemented Kentucky All Schedule Prescription Electronic Reporting (KASPER) in 
1999. Initially KASPER allowed prescribers, pharmacies, and law enforcement to request 
reports that detailed a patient’s controlled substance prescription history. KASPER 
became fully electronic in 2005 which allowed pharmacists and prescribers to utilize the 
KASPER reports in real time to make more informed decisions regarding patient care. 
According to Kentucky’s Cabinet for Health and Family Services, when a patient’s 
KASPER report is created, the report will show the following: date range for the report, 
patient names and date of birth, prescription information such as date filled, quantity, day 
supply, doctor name and city, drug name and strength, and pharmacy name and city. To 
evaluate the effectiveness of KASPER an independent study was done in 2010 that 
revealed “16% of licensed pharmacists and 27.5% of licensed controlled substance 
prescribers were registered with the PDMP” (Wixson et al., 2015). These statistics were 
further evidence that overall less than 25% of healthcare professionals access PDMPs to 
obtain controlled substance reports (Green et al., 2011).  
 In 2012 the Kentucky General Assembly passed House Bill 1 (HB1). HB1 
adopted the PMDP mandated use model and made changes to the prescribing and 
monitoring of controlled prescription drugs. HB1 included “1) mandatory KASPER 
registration and use by controlled substance prescribers and dispensers, 2) a requirement 
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that pain management clinics be owned by licensed physicians, 3) licensure standards for 
practitioner-owned pain management clinics (a responsibility of the medical licensure 
boards), 4) licensure standards for grandfathered non-physician-owned pain management 
clinics (a responsibility of the Kentucky Office of Inspector General), and, 5) prescribing 
guidelines for Schedule II and Schedule III controlled substances containing hydrocodone 
(American Public Health Association).” HB1 was intended to assist prescribers in making 
appropriate treatment decisions, to readily identify patients in need of substance abuse 
treatment, and to identify “doctor shoppers.” 
 A research team from the University of Kentucky College of Pharmacy published 
an 88-page report in 2015 evaluating the impact of HB1. Their findings concluded within 
the few years of HB1 the number of prescriptions dispensed for all Schedules of 
controlled substances decreased by 4 to 8%. Prescribers registered with KASPER 
increased by 262%, while pharmacists registered with KASPER increased by 322%. HB1 
may have effectively addressed inappropriate prescribing; there was a significant 
decrease in high dose oxycodone prescribing and patients receiving the medical “holy 
trinity” decreased by 30%. The “holy trinity” is a concurrent drug therapy that is the 
combination of an opioid, a benzodiazepine (commonly prescribed medications are 
Valium and Xanax), and skeletal muscle relaxants, especially carisoprodol. This drug 
combination has been reported to potentiate the high “through unique interactions with 
colocalized μ‐opioid and GABAA receptors… inducing a synergistic increase in 
dopamine in the nucleus accumbens (NAc) and depression of respiration (Horsfall and 
Spragye 2016)”. It should also be noted prescribing of buprenorphine/naloxone for OUD 
treatment increased by over 40%. Additionally, the study evaluated the possible impact 
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on “doctor shopping” as it was a key proponent within HB1. For the purpose of 
consistency, the study defined doctor shopping “as a patient receiving multiple 
prescriptions from four or more different prescribers and filled at four or more different 
pharmacies within a three-month period.” There was a decrease by over 50% in the 
number of patients that met this definition. The evaluation noted “treatment admissions in 
Kentucky for prescription opioids decreased at a higher rate while treatment admissions 
related to heroin increased at a higher rate compared to surrounding states. Similarly, 
hospital discharges and deaths due to prescription opioid overdose in Kentucky declined 
post-HB1 while hospital discharges and deaths due to heroin overdose increased 
(Freeman et al., 2015).” The impact of KASPER is notable in reducing doctor shopping 
and abuse of prescription drugs; however, the statistics paved way for research to be 
executed investigating the possible role PMDPs may play in shifting the high rates of 
abuse, addiction, and overdose from prescription opioids to heroin.  
 In 2018, Dr. Anjali Dhanda published a study examining opioid use in patients 
presenting for Suboxone® (BUP/NAL) at the University of Louisville Physicians 
Outpatient Center, Robley Rex VAMC, and two private practices in Louisville, KY.  The 
study determined that after the passage of Kentucky House Bill 1 in 2012 (HB1), there 
was a significant increase in patients reporting heroin use and opioid agonists in 
comparison to non-heroin opioids when presenting for treatment. Data were collected 
from a multi‐site chart review study that extended from January 1, 2009 to July 1, 2016. 
The study included a series of multinomial logistic regressions using Stata version 13 to 
determine strength of association between Pre‐Post HB1, clinical setting, sex, age, and 
type of substance reported at BUP/NAL intake appointment. Type of substance reported 
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was used as the dependent variable. This data identified heroin as the most commonly 
used drug by patients who sought BUP/ NAL treatment after the enactment of HB1 and 
also a significant increase in use of an opioid agonist. The study defines an opioid agonist 
as methadone or any buprenorphine containing product. The data also supported a rise in 
heroin use with the decline in non-heroin opioid use after HB1. Limitations to the study 
included the small sample size of four locations that could lead to generalized 
conclusions. Additionally, there was nothing in the article relating to the availability, 
cost, popularity of heroin from year to year in the region. Even though a causal 




 While Kentucky and other Appalachian states are hit hardest by the opioid 
epidemic (Appalachian counties had an opioid overdose death rate that was 72% higher 
than in non-Appalachian counties throughout the country; U.S Department of Health and 
Human Services 2020), there have been studies done across the country investigating the 
shift from prescription opioid to heroin abuse. Heroin is an illegal opioid that is processed 
from morphine. Pure heroin is a white powder than can be snorted or smoked, while 
impure “black tar” heroin is a dark color, resulting from processing methods that create 
impurities. “Black tar” heroin is most commonly injected into veins or muscles under the 
skin (National Institute on Drug Abuse 2014). Similar to morphine, the analgesic effects 
of heroin are enacted when the two active metabolites, 6-O-acetylmorphine and 
morphine, bind to the mu-opioid receptors of the central nervous system. The mu-
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receptors also enact respiratory depression, euphoria, and physical dependence (Hosztafi 
2003). The National Survey on Drug Use and Health reported in 2016 that about 948,000 
Americans used heroin in the past year. Additionally, the number of people using heroin 
for the first time in 2016 was revealed to be 170,000—nearly double what it was in 2006 
(National Institute on Drug Abuse). There have been many studies conducted in the last 
decade that reveal there is a potential correlation between PDMPs, the reformulation of 
Oxycontin®, and the spike of heroin use during the early 2010’s. 
 Given the notable increase in heroin and decrease in prescription opioid abuse, a 
study published by Dr. Theodore Cicero, PhD et al., at Washington University, St. Louis 
examined the relationship between heroin and prescription opioids (see Figure 1). 
Anonymous surveys were completed by 15,227 patients with opioid dependence. The 
surveys were collected quarterly from January 1, 2008 to September 31, 2014.  
 
Figure 1: National Rates of Abuse of Opioids among 15,227 Respondents. Adapted from “Shifting Patterns 
of Prescription Opioid and Heroin Abuse in the United States,” by T. J Cicero et al., 2015, The New 





 Figure 1 illustrates the unadjusted rates of abuse of prescription opioids only, 
abuse of prescription opioids and abuse of heroin only. From 2008 to 2010 prescription 
opioid abuse remained consistent at 70%; however, it began to decrease steadily with an 
average annual reduction of 6.1% to less than 50% in 2014. Although exclusive heroin 
abuse was low in the study’s population in comparison to the other two variables, it more 
than doubled (from 4.3% to 9.0%) from 2008 to 2014. Abuse of both heroin and 
prescription opioids contemporaneously revealed an average annual increase from 10.3%, 
from 23.6% in 2008 to 41.8% in 2014 (Cicero et al., 2015). An online interview was also 
performed to gather supplemental qualitative information from the patients. While only 
267 of the 15,227 agreed to participate, nearly 49% of those participants reported abusing 
prescription opioids prior to heroin use and 73% gave the rationale of accessibility and 
cost regarding their transition to heroin (Cicero et al., 2015).  
Similar to Dhanda et al.’s study mentioned previously, Branham’s study argues 
that there are unintended effects of the implemented prescription drug monitoring 
programs (PDMPs). Branham argues that PDMP’s may move prescription opioid users to 
heroin as heroin shares many effects of prescription opioids and is easier to access—
making it a good alternative from an addict’s perspective. The case study rests on the 
evaluation of the impact of PDMPs on heroin abuse across twenty-one different states 
through use of treatment admissions records obtained from the Treatment Episode Data 
Set. The relationship between heroin admissions and prescription opioid admissions was 
significant for the average data (β = 0.41, p = 0.0017) and the 5-year data (β = 0.5, p = 
0.036), both showing positive associations between heroin and prescription drug 
admissions in states during the post PDMP implementation period. The data supported 
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the argument; however, there were some noteworthy limitations, the most prominent 
being the sample size. The data set used in this study reviewed only those who seek 
treatment.  Therefore, it cannot be concluded with certainty that this information 
represents the drug abusing population to the greatest capacity.  
 Further examining the associated rise in opioid dependence and heroin addiction, 
interview data was collected in King County, Washington at five syringe exchange sites. 
The study was conducted with intent to determine the proportion of current heroin users 
who were able to report being “hooked on” prescription opioids before heroin use and 
determine if there are different characteristics of heroin users based on their history with 
prescription opioids. The results indicated among the respondents who used heroin in the 
prior four months, 39% reported abuse of prescription opioids first. Regression analysis 
revealed those abusing prescription opioids prior to heroin were “significantly more 
likely to be younger, to have reported recent sedative medication use, and less likely to 
have reported recent crack use” (Peavy et al., 2012). A notable limitation to the study is 
the use of convenience sampling the studied followed, which may generalize the 
population of heroin users in King County, Washington to only the five syringe exchange 
sites interviewed. Despite limitations, the study illustrated the relationship the can be 
drawn from heroin and prescription opioid abuse.  
 Heroin abuse is currently not limited geographically or demographically. Data has 
revealed that over the last 50 years heroin users entering treatment has evolved from a 
common urban, minority centered to problem to one much more widespread. More recent 
heroin users were men and women in their twenties “living in less urban areas (72.5%) 
who were introduced to opioids through prescription drugs (75.0%; Cicero et. al, 2014).”  
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The recent users exhibit similar drug use patterns to those who misused prescription 
opioids. The growing demographic of heroin users may be attributed to the fact that 
heroin is cheaper and more accessible, and that there is an acceptance of heroin use 
among those who abuse prescription opioids.  
 Another factor that potentially helped ignite the transition to heroin is the 
reformulation of OxyContin®. OxyContin® originally rose to popularity for recreational 
drug users because the drug offered more of the active ingredient, oxycodone, than other 
prescription opioids due to its extended release nature. The extended-release formulation 
releases oxycodone every 12 hours; however, the properties could be easily circumvented 
through crushing or chewing for uses like snorting or using intravenously for a quick 
high. In 2010 Purdue Pharma replaced the drug on the market with an abuse-deterrent 
formulant (ADF) that made it more difficult to abuse the drug in the common fashion 
(Evans et al., 2019). The FDA acknowledged that ADFs do not eliminate all drug abuse; 
however, the reformulation was intended to prevent the tablets from being chewed or 
crushed for sniffing, smoking, or injecting by making it harder, viscous in water, and less 
“liked” for intranasal abuse (FDA 2020). By the early 2010’s there was a growing 
literature regarding the potential of prescription opioid misuse being key into trajectories 
into injection drug use and/or heroin. The compiled research raises the question: is the 
promotion PDMPs and ADFs an effective policy to reduce drug abuse or is it 






SPREAD OF DISEASE BY INJECTION DRUGS  
 The significant increase in heroin abuse also brought an increase in spread of 
blood-borne infections, specifically, hepatitis C (Hep C) and human immunodeficiency 
virus (HIV) by injection drug use. The primary transmission route for Hep C and HIV is 
through contaminated needles, syringes, and other injection drug equipment, such as a 
cooker. This can happen if a contaminated syringe is used to liquefy and apportion the 
shared drug. A 2005 study conducted by Dr. Stephan Koester, PhD, Jason Glanz, and 
Anna Barón revealed that among 304 heroin-injecting networks, 82% reported dividing 
the drug as a liquid, 86% reported using a cooker, 67% reported using a reservoir of 
water that syringes had been rinsed in to mix drugs (Koester et al., 2005). Injection drug 
users are at the greatest risk for developing these infectious diseases. Globally, 60% to 
80% of injection drug users are Hep C positive (Nelson et al., 2011). In the United States, 
rates of Hep C infection among current and past injection drug users are 70% to 90% 
(Wang et al., 2011). Additionally, nearly 300,000 individuals are coinfected with HIV 
and Hep C—representing 25% to 30% of all HIV infected individuals and 5% to 10% of 
all Hep C infected individuals (Diaz et al., 2001).  
 In March 2010 injection drug users in San Diego between the ages of 18-40 who 
had injected illicit drugs within the previous six months, California were recruited for a 
cross-sectional study of hepatitis C and HIV infection risk. The survey assessed 
sociodemographics, drug use history, HIV and Hep C virus risk behaviors and 
perceptions, and medical history. Additionally, the parent study had questions on 
prescription-type opioid use to compare prescription opioid use prior to transitioning to 
heroin with other heroin injection drug users.  Out of 123 heroin injection drug users, 49 
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(39.8%) reported that they had used prescription-type opioids illicitly prior to the first 
time they used heroin. The primary prescription-type opioids that these individuals were 
abusing included: Oxycontin®/oxycodone (75.5%), Vicodin™/hydrocodone (69.4%), 
morphine (34.7%).  However, participants also reported using Percocet™ (20.4%), 
fentanyl (20.4%), Dilaudid™/hydromorphone (16.3%), methadone (14.3%), Demerol™ 
(8.2%), and other prescription-type opioids (4.1%; Pollini et al., 2011). 
 Millennials (born between 1981 and 1996) have been at the forefront of the opioid 
crisis, in both rural and urban areas, as well as the fastest growing generation for those 
infected with Hep C. Since 2013, the number of Hep C related deaths in the United States 
has exceeded the number of deaths associated with HIV and 59 other infectious diseases 
combined (Liang and Ward 2018). A study published in 2019 by Michelle Rose, MBA, et 
al., further examined the correlation. The argument was supported by partnering with 
Norton Healthcare and screening all individuals per standard risk-based criteria, except 
for pregnant women, for Hep C from 2016 to 2018. The data was analyzed for 
demographic shifts. The data demonstrated 2,615 (3%) of a total of 86,243 individuals 
screened for Hep C infection tested positive for chronic Hep C. The average age of those 
infected significantly decreased by an average of 3.7 years annually. The proportion of 
Hep C positive millennials increased over the three years, while baby boomers 
significantly decreased over the time period (Rose et al., 2019). The results support that 
Hep C has become a predominantly millennial disease and correlates with trends seen 
with the opioid epidemic.   
 Because most injection drug users who become infected with Hep C do so as 
young adults, there is a greater risk of chronic Hep C. Chronic Hep C is now typically 
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curable with oral medications, such as Daklinza, Zepatier, or Mavyret, taken every day 
for two to six months; however, many infected with Hep C do not know they are infected 
because symptoms may take decades to appear, until the virus damages the liver enough 
to cause the signs and symptoms of liver disease (Mayo 2020). Chronic Hep C can cause 
serious health problems, such as liver damage, cirrhosis, liver cancer, and liver failure 
(CDC 2020). This chronic condition leads to potential years of health care expenses, as 
well as the risk of transmitting it to others if continuously left untreated. Additionally, 
continued substance use among infected individuals raises the risk for developing more 
serious liver disease (Schulte et al., 2016).  
 
NEONATAL ABSTINECE SYNDROME  
 In addition to the devastating numbers of addiction and overdose, there are other 
consequences to the opioid epidemic. One population hit with complications extending 
from the epidemic is pregnant woman and infants. Neonatal abstinence syndrome (NAS) 
is a withdrawal syndrome that can occur in newborns exposed to certain drugs of abuse, 
including opioids, during pregnancy (CDC). These drugs pass through the placenta that 
connects the child to its mother in the womb causing the infant to form a dependence on 
the drug. This causes withdrawal to occur as the drug is slowly cleared from the infant’s 
system with symptoms often beginning within one to three days after birth. Symptoms of 
NAS depend on the type of drug, how much and how often the mother was taking the 
drug, genetic factors, and whether or not the baby was carried full term. With regard to 
opioids, symptoms of NAS may include excessive and high-pitched crying, mottling, 
diarrhea, fever, tight muscle tone, overactive reflexes, rapid breathing, seizures, and 
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tremors (Medline). Infants exposed to opioids during pregnancy are more likely to be 
born premature, have poor fetal growth, be born with birth defects, have longer hospital 
stays after birth, and be re-hospitalized within 30 days after being born. A recent study 
published in 2018 revealed that “children with a history of NAS were significantly more 
likely to have a subsequent educational disability (Fill et al., 2018).”  
 Coinciding with the increase in opioid use among pregnant women, “NAS grew 
nearly 7-fold from 2000 to 2014” (Jansson and Patrick 2020). Rates of OUD in 
pregnancy grew substantially from 1999 to 2014 with over 30,000 infants diagnosed with 
NAS in 2014 (Winkelman et al., 2018). In 2016 the Healthcare Cost and Utilization 
Project reported “seven newborns were diagnosed with NAS for every 1,000 newborn 
hospital stays … that is approximately one baby diagnosed with NAS every 19 minutes in 
the United States, or nearly 80 newborns diagnosed every day” (CDC 2020). A study 
published in 2019 by Dr. Strahan, PhD and company explored the increasing cost of 
NAS. The study reported “infants with NAS had a 15.9-day (20.4-day) mean (SD) length 
of stay and total overall hospitalization costs were $572.7 million. The average cost per 
infant with NAS was $22,552. Neonatal abstinence syndrome rates were highest among 
Medicaid-covered births (12.3 per 1000) and those without insurance (7.0 per 1000). 
Total costs were highest for births covered by Medicaid ($477.0 million; Strahan et al., 
2019).” 
 The consequences and possible complications related to NAS are devastating and 
warrant an extensive look at treatment. Pregnant women with OUD are recommended to 
not quickly stop opioid use during pregnancy as it may lead to preterm labor, miscarriage, 
or fetal distress, and are instead encouraged to use Medication-Assisted Treatment 
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(MAT) during pregnancy. MAT uses a combination of pharmaceutical treatment and 
behavioral counseling and therapy (CDC 2020). Methadone and buprenorphine are 
frequently used for treating opioid dependent pregnant women. Methadone has been 
recommended as the standard of care for pregnant women with OUD, while 
buprenorphine was added to the mix in more recent years. Treatment of pregnant women 
with methadone or buprenorphine improves infant outcomes by stabilizing fetal levels of 
opioids. The National Institute on Drug Abuse reported women treated with methadone 
or buprenorphine had infants with “lower risk of NAS, less severe NAS, shorter 
treatment time, higher gestational age, weight, and head circumference at birth” in 
comparison to untreated pregnant women (National Institute on Drug Abuse 2017).   
Infants born with NAS are treated with non-pharmaceutical methods focused on 
supportive care, such as swaddling, breastfeeding, rooming in, and skin-to-skin exposure 
(National Center on Substance Abuse and Child Welfare). Pharmaceutical methods, such 
as methadone or morphine, are also used when warranted by greater severity of 
symptoms (Finnegan 2013). Infants are weaned off treatment medication that can extend 
over three weeks whenever symptoms subside. Pharmaceutical treatment is required for 
“50 to 70% of infants” and is based on genetic factors, other drug exposures, gestational 
age, breastfeeding, and practice of rooming-in (a practice where postnatal mothers and 
infants stay together in the same room for 24 hours a day from the time they arrive in 
their room after delivery) (Logan et al., 2013). Pharmaceutical treatment is formulated 
based on the cumulative threshold score, taken from most commonly the Finnegan 
Neonatal Abstinence Severity Scoring System (nas 2018).   
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 While there are many proactive measures in place that aid in managing NAS, it is 
important to examine the current research to expand the best possible healthcare available 
for pregnant women with OUD. Access to contraception is underutilized as nearly nine 
out of ten pregnancies among women with OUD are unplanned (Hurley et al., 2020). 
This statistic makes light to the lack of access to contraception and sex education in 
young adults today. Substance Abuse and Mental Health Services Administration 
(SAMHSA) also reported about 50% of women in treatment for OUD are using 
contraception in comparison to about 80% of women in the general population. 
Expanding access to contraception and discussing family planning options with women 
with OUD may reduce future unplanned pregnancies and the overall burden of NAS. In 
addition to promoting access to contraception, addressing underlying causes of OUD and 
training healthcare professionals to eliminate any preexisting stigma associated with 
pregnancy and OUD is pivotal for holistic care.  
  
ILLICIT OPIOIDS 
 Prescription opioids may be directed through resale or theft to illicit markets that 
are not supplied through the United States healthcare system. Illicit markets were 
commonly reserved for heroin; however, recently, the illicit market has expanded to most 
notably encompass synthetic opioids, such as fentanyl. Fentanyl is an opioid that is 50 to 
100 times more potent than morphine. The drug is sold as a powder, dropped onto blotter 
paper, put in eye droppers and nasal sprays, or made into pills that look like other 
prescription opioids. Fentanyl and its analogs, such as acetyl fentanyl, ocfentanil, and 
carfentanyl, are widely synthesized in laboratories and adulterated with illicit drugs, 
 
 26 
contributing to the exponential growth in the number of drug-related overdose deaths 
(CDC 2019). 
Synthetic opioids are commonly packaged and sold in bulk from abroad to drug 
trafficking organizations or even as counterfeit pills made to look like popularly diverted 
prescription opioid medications. Manufactured synthetic fentanyl has many diverse 
sources. Illicit drugs are often trafficked through complex pathways. One noteworthy 
pathway being bulk shipments from China to drug trafficking organizations in Mexico, 
then traveling across the Southwest border (Phillips et al., 2017). Fentanyl and its analogs 
are most often sold through illegal drug markets and  are also often mixed into and/or 
with heroin, cocaine, methamphetamine, and counterfeit pills (CDC 2019).  
Fentanyl in wholesale markets costs about one-tenth as much as heroin, but has 
been shown to be 10-25 times more potent than heroin (Phillips et al., 2017). The cost is 
an added incentive to not only transition to fentanyl, but to adulterate other drugs with it. 
Additionally, the reduced costs contribute to the increase in counterfeit prescription 
opioid pills laced with or containing only fentanyl.  
Knopf’s 2016 report published in Alcoholism & Drug Abuse Weekly demonstrates 
there is an increase in opioid overdoses, showing significant increases in heroin and illicit 
fentanyl. The report states heroin and illicit fentanyl were responsible for most of the 
increase in overdoses in regard to opioids. The report rests on data from the CDC that 
demonstrated between 2013 and 2014, shortly after the strict implementation of PDMPs, 
overdose rates involving methadone were unchanged, but deaths involving opioid pain 
relievers increased 9%, deaths involving heroin increased 26% and deaths involving 
synthetic opioids (other than methadone) increased 80%. The majority (approximately 
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61%) of the drug overdoses in 2014 involved some type of opioid. A noteworthy 
limitation to the study is the possibility that some overdose deaths were counted more 
than once. This happens because some deaths involve more than one type of opioid and 
these deaths were included in the rates for each category (Knopf 2016).  
The numbers Knopf reported at the beginning of the third wave of the epidemic 
have not plateaued. Illicit fentanyl abuse has continued to consistently increase over the 
course of the decade. The CDC recently reported rates of overdose deaths involving 
synthetic opioids increased over 16% from 2018 to 2019, overdose deaths involving 
synthetic opioids were nearly 12 times higher in 2019 than in 2013, and more than 36,000 
people died from overdoses involving synthetic opioids in 2019. Additionally, the latest 
provisional drug overdose death counts through May 2020 suggest an acceleration of 
overdose deaths during the COVID-19 pandemic (CDC 2020). Opioids accounted for 
about 75% of all overdose deaths during the early months of the pandemic--about 80% of 
those included synthetic opioids (Baumgartner and Radley 2021). The recent acceleration is 
likely due to the nature of isolation and loneliness attributed from the recent pandemic.  
 
CURRENT OUD TREATMENT 
 There are currently three FDA approved medications used for treatment of OUD: 
methadone, buprenorphine, and naltrexone. The goals of these medications are to reduce 
or eliminate withdrawal symptoms, block the effects of illicit opioids, and reduce or 
eliminate cravings to use opioids. Buprenorphine FDA-approved products for opioid 
dependence include Bunavail (buprenorphine and naloxone) buccal film, Cassipa 
(buprenorphine and naloxone) sublingual film, Probuphine (buprenorphine) implant for 
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subdermal administration, Sublocade (buprenorphine extended‐release) injection for 
subcutaneous use, Suboxone (buprenorphine and naloxone) sublingual film for sublingual 
or buccal use, or sublingual tablet, Subutex (buprenorphine) sublingual tablet, and 
Zubsolv (buprenorphine and naloxone) sublingual tablets (FDA 2019). Buprenorphine is 
an opioid partial agonist. The most common treatment buprenorphine treatment is 
Suboxone (buprenorphine/naloxone). Naloxone is an opioid antagonist that blocks the 
opioid receptors. Used independently, naloxone or its brand name Narcan® is used to 
reverse opioid overdose. However, when combined with buprenorphine, it provides all of 
the benefits of the stand-alone buprenorphine product, but adds a deterrent to misuse. 
Suboxone minimizes the risk of overdose and was formulated to have a lower risk of 
dependency than that of methadone. Other less common FDA-approved medications for 
treatment of opioid dependence are Dolophine (methadone hydrochloride) tablets,  
Methadose (methadone hydrochloride) oral concentrate, and Vivitrol (naltrexone for 
extended-release injectable suspension) intramuscular (FDA 2019).  
 Randomized clinical trials have concluded methadone and buprenorphine were 
found to be more effective in reducing illicit opioid use in comparison to no medication. 
Additionally, methadone and buprenorphine are associated with reduced risk of overdose 
death (SAMHSA 2018). While there is continued research in place comparing naloxone 
and buprenorphine with placebos and no pharmaceutical treatment. Individuals may take 
medication for OUD on a short-term or long-term basis. The most common use of 
pharmaceutical OUD treatments are maintenance treatment, medication taper, and 





 In 2017 the American College of Physicians (ACP) released a statement calling 
addiction to be treated as any other chronic condition. The president of ACP, Dr. Damle, 
MD, MS, MACP stated “substance use disorders are treatable chronic medical 
conditions, like diabetes and hypertension, that should be addressed through expansion of 
evidence-based public and individual health initiatives to prevent, treat, and promote 
recovery.” Dr. Damle’s quote encompasses the holistic approach that must be taken to 
create a curative path to effectively treat OUD.  
 A study published in 2019 by Dr. Chen, PhD et al., projected the future of 
overdose deaths in the United States. A system dynamics model of the US opioid 
epidemic projected outcomes of simulated individuals who engage in nonmedical 
prescription or illicit opioid use from 2016 to 2025 was designed and the analysis was 
performed by calibrating the model from 2002 to 2015 data from the National Survey on 
Drug Use and Health and the Centers for Disease Control and Prevention. The study 
revealed “the annual number of opioid overdose deaths is projected to increase from 
33,100 in 2015 to 81,700 in 2025…from 2016 to 2025, 700,400 in the United States are 
projected to die from opioid overdose, with 80% of the deaths attributable to illicit 
opioids (Chen et al., 2019).” The projected numbers of significant increases in abuse, 
addiction, and overdose is not to diminish the vital work that has been done by healthcare 
professionals over the last two decades; however, implementations of PDMPs, OUD 
treatment, and reformulation of prescription opioids have only had a modest effect over 
the opioid epidemic. It is urgent that the current policies in regard to OUD are 
reexamined to combat the changing course of the epidemic.  
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 With the widespread implementation of mandated PDMPs potential effects on the 
illicit drug market should be taken into consideration when each state reevaluates their 
individual program. The increased demand for illicit opioids is noteworthy and 
appropriate steps must be taken to mitigate those effects. Additionally, more research 
studies should be invested in to better understand and characterize the relationship 
between prescription and non-prescription opioid abuse. There is only a small body of 
literature currently out on the potential of prescription opioids as a precursor to illicit 
opioids, making it a vital subject to be studied in the future.  
 In order to potentially reduce the high-risk consequences of injecting opioids, 
testing for Hep C and HIV should be made more readily available, specifically in low-
income areas geographically, such as rural Central Appalachia (West Virginia, Southwest 
Virginia, Eastern Kentucky, Southeast Ohio, East Tennessee, and Western North 
Carolina) where the numbers of injection drug use are among the highest rates of use and 
overdose across the US. The unmatched rates are most likely due to the many barriers to 
treatment and testing Central Appalachia faces, including a lack of access to health care 
and lack of health care providers with specialized training (Moody et al.,2017) . More 
accessible testing could prevent transmission by early identification. Additionally, Hep C 
and HIV testing could take place in facilities that also administer pharmaceutical OUD 
treatment and syringe service programs. Population-based screening is another potential 
strategy for identifying those infected and connecting them to treatment in a clinical 
environment an individual is comfortable in. 
 Population-based screening may also work well for pregnant women with OUD, 
another population with high-risk consequences due to OUD. Continuing behavioral 
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therapy and counseling after the pregnancy may motivate the women to continue with 
treatment with the intent of nurturing coping skills and reducing the risk of returning to 
substance use. More accessible testing for Hep C and HIV and screening women for 
depression, anxiety, and other mental health diagnoses will create a more in-depth 
approach that will allow the healthcare provider to better create the best treatment for 
each individual woman.  
In addition to widespread testing and screening, improving access to medications 
for OUD is another potential strategy. The efficacy of pharmaceutical OUD treatments, 
such as methadone, buprenorphine, and naloxone, in reducing complications and fatal 
overdose and improving remission rates has been proven through decades of research; 
however, universal treatment is lacking (Wakeman et al., 2018). Almost 80% of 
Americans with OUD do not receive medical treatment (Saloner and Karthikeyan 
2013).  Access to addiction treatment should be promoted at both primary care offices 
and pharmacies. It is pivotal to make it easier to obtain OUD treatment than to get illicit 
opioids.  
Healthcare providers and pharmacists should see a shift in curriculum relating to 
OUD. There is a lack in clarity and consistency throughout medical and pharmacy 
schools. It is imperative to effectively equip physicians to appropriately prescribe opioids 
and other addictive substances. Currently opioid prescription training is “a fairly short-
term, stand-alone segment of medical education (Singh and Pushkin 2019).” Extending 
the training and addressing the ethics of the matter to remove any stigma towards OUD 




Education on the subject should not be limited to healthcare professionals. It 
would be greatly beneficial to develop a program on this subject aimed for children. Drug 
Abuse Resistance Education (DARE) was founded in 1983 and was greatly promoted in 
school systems. DARE was the youth directed byproduct of America’s “War on Drugs.” 
An article published through American Addiction Centers in 2021 revealed in short why 
the program did not work. One major factor being the hysteria that was ramping through 
America at the time had the program focus on punitive consequences rather than 
rehabilitative education (Berry 2021). The struggles of DARE should be noted and used 
to build a more believable program. Starting the program in school systems in rural areas 
could potentially be the beginning of another curative path.  
The compiled research conveys the changing nature of the epidemic.  Addressing 
overprescribing of opioids through prescription monitoring and improved pain 
management has been pivotal in combatting the crisis; however, there is still much work 
to be done as the use of illicit opioids is historically high and only expected to increase. 
To prevent unknowingly promoting another addiction (and ultimately change the course 
of, but not eliminate, the epidemic) it will require a multipronged strategy, that consists 
of the healthcare system overcoming the stigma of OUD and developing innovative ways 
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